.
After inhalation of frusemide the maximum fall in FEV1 was reduced to 14-3% after placebo pretreatment and to 21P8% after indomethacin pretreatment; the difference between placebo and indomethacin pretreatment was significant (mean difference 75%, 95% limits 0-6%, 14-4% Inhaled frusemide has been shown in the last few years to protect asthmatic subjects from bronchoconstriction in response to various indirectly acting stimuli, including exercise,' ultrasonically nebulised distilled water,2 adenosine 5'-monophosphate,3 sodium metabisulphite,4 and the early and late response to allergen.5 It has little or no effect on the bronchoconstriction following directly acting agonists, such as methacholine3 4 and histamine. 6 The mode of action of frusemide in asthma is uncertain but is of interest as it might shed light on the pathophysiology of asthma. 7 One possibility is that frusemide inhibits epithelial sodium-potassium-chloride (Na/K/Cl) cotransport and thereby alters neural activity48 or inflammatory cell activation35 through a direct action or by altering the osmolarity of airway lining fluid. The lack ofeffect ofsystemic frusemide in asthma argues against this mechanism, however,7 as does the fact that bumetanide, a more potent inhibitor of Na/K/Cl cotransport, has no effect on asthma induced by sodium metabisulphite or exercise. 9 10 We have explored an alternative hypothesis -namely, that the effects of frusemide are due to generation of cyclooxygenase products in the airway. Frusemide enhances synthesis of prostaglandin E2 (PGE2)," and intrarenal synthesis of this prostanoid is thought to play a part in the acute vascular changes observed after intravenous administration of frusemide.'2 There is evidence that bumetanide does not share these effects when administered at equivalent diuretic doses.'3 As inhaled PGE2 has been shown to protect against sodium metabisulphite and exercise induced asthma and the early response to allergen,""'6 the beneficial effects of inhaled frusemide may be related to local airway production of PGE2. We report the effect ofthe cyclooxygenase inhibitor indomethacin on the protection afforded by inhaled frusemide against exercise induced asthma.
Methods

SUBJECTS
We studied 10 subjects (eight male) aged 18-52 years, with mild stable atopic asthma and a 20% or more fall in FEV1 with exercise, who required only inhaled drugs. All subjects were taking an inhaled f2 agonist and five an inhaled corticosteroid (100-1000 jug beclomethasone a day). One subject was a current smoker and one a past smoker. All had a baseline forced expiratory volume in one second (FEV1) of ,70% predicted or more. None gave a history of aspirin induced asthma or developed bronchoconstriction in response to oral indomethacin when challenged in the laboratory. f2 Agonists were withheld for six hours before each exercise test. Subjects gave full signed consent to participate in the study, which was approved by the City Hospital ethics committee. 797 Respiratory Medicine Unit, City Hospital,
Mean (95% confidence interval) values for baseline FEV,, maximum fall in FEV, and change in FEV, over 30 minutes (A UC) for indomethacin andfrusemide treatment, and within subject differences from indomethacin and frusemidefor the other three treatment regimens 
ANALYSIS
The airway response to exercise was assessed as the maximum percentage fall in FEV, and as the area under the plot of percentage change in FEV, against time (AUC), the FEV, immediately before exercise (10 minutes after inhalation) being used as baseline. Baseline FEV,, maximum percentage fall in FEV,, and AUC were compared within subjects by analysis of variance by means of the generalised linear interactive modelling (GLIM) statistical package. FEV, values before and after inhalation were compared by a paired t test. The inhibitory effect of frusemide on exercise induced asthma was estimated by expressing the difference in AUC over 30 minutes between the treatment and placebo day as a percentage of the placebo AUC. The percentage inhibition was not normally distributed and is expressed as a median and range; it was compared within subjects by the Wilcoxon signed rank sum test.
Results
There was a small increase in FEV, after inhalation of frusemide following indomethacin pretreatment (mean 0 16 1, 95% confidence limits (CL) 0 035, 0 289; p < 0.02) but the pre-exercise (baseline) FEV, did not differ on any of the treatment days (table) .
After inhalation of placebo exercise caused a similar mean maximum fall in FEV, with placebo pretreatment (26%) and indomethacin pretreatment (25 2% with placebo pretreatment (mean difference 7-5%, 95% CL 0 6, 14 4%; p < 0 05).
The area under the plot of change in FEV1 against time following frusemide was compared with that following placebo inhalation and pretreatment. The median reduction in AUC after frusemide was 62% with placebo pretreatment and 13% with indomethacin pretreatment; the difference was significant (p < 0.01).
Discussion
This study has confirmed that inhaled frusemide protects against exercise induced asthma. The 62% reduction in the airway response to exercise after inhaled frusemide is in agreement with the findings of Bianco et al' and others.'0 We also confirmed that indomethacin alone, at a dose that abolished the rise in urinary thromboxane metabolites'7 and increase in prostaglandin concentrations in bronchoalveolar lavage fluid"8 after allergen challenge in asthmatic subjects, has no effect on the airway response to exercise.'9 Our main finding was that treatment with indomethacin for three days reduced the effect offrusemide in protecting against exercise induced asthma. This reversal of the protective effects of frusemide by a cyclooxygenase inhibitor provides strong evidence for our hypothesis that the beneficial effects of frusemide in exercise induced asthma are due to production of inhibitory prostanoids.
Both PGE2 and prostacyclin (PGI2) are major cyclooxygenase products of human lung20 and in animals frusemide has been shown to enhance synthesis of PGE2 by renal tubular epithelium" and PGI2 by vascular endothelium.2' In man PGE2 is produced by airway epithelium22 and PGI2 by pulmonary vascular tissue.20 As frusemide is only effective in asthma when inhaled, enhanced production of epithelium derived PGE2 is the more likely mechanism.
This mechanism is consistent with the lack of effect of bumetanide in asthma. Bumetanide, like frusemide, inhibits the Na/K/Cl cotransporter but, in contrast to frusemide, does not inhibit the airway response to exercisel' or inhaled sodium metabisulphite.9 Intrarenal synthesis of PGE2 in response to frusemide is thought to play a part in the vascular changes observed after intravenous frusemide." 1223 Frusemide stimulates production of PGE2 by increasing availability of arachidonic acid23 and it may in addition inhibit the conversion of PGE2 to PGF2, by PGE2-9-ketoreductase24 and the metabolism of PGE2 by PGE2- 15- hydroxydehydrogenase.24 25Bumetanide has no effect on the latter enzyme25 and this, together with the absence of peripheral vascular changes after intravenous bumetanide,'3 suggests that frusemide has a greater effect on prostaglandin synthesis than bumetanide in relation to Na/K/ Cl cotransport.
Our suggestion that frusemide is acting through release of inhibitory prostanoids assumes that these prostanoids protect predominantly against bronchoconstrictor challenges that act indirectly (through mast cell degranulation, neural pathways, or inflammatory cells) rather than those that act directly on airway smooth muscle. There is some evidence to support this view. PGE2 does not inhibit histamine induced contractions of human airway preparations in vitro and may cause contraction rather than relaxation.26 PGE2 does, however, have inhibitory effects on cholinergic contractions of human airway preparations after electric field stimulation27 and in higher concentrations on lung mast cell mediator release28 and eosinophil activation.29 Inhaled PGE2 inhibits the bronchoconstrictor response to exercise, ultrasonically nebulised distilled water,15 allergen,'6 and sodium metabisulphite in subjects with mild asthma but has little or no effect on bronchial reactivity to methacholine.'4 Studies with cyclooxygenase inhibitors support a protective role for endogenous inhibitory prostanoids, showing a reduction in the refractoriness commonly observed after recovery from bronchoconstriction induced by exercise'9 and other indirect challenges.30 3 The fall in FEV, after exercise with frusemide was greater after indomethacin than placebo despite a small increase in FEV, on the indomethacin treatment day after inhalation of frusemide. The mechanism of this small bronchodilator response is not clear but it may represent an effect of frusemide that is independent of cyclooxygenase products. We considered whether the interaction between indomethacin and frusemide could be explained on grounds other than inhibition of prostaglandin synthesis. Both drugs are weak organic acids and may compete for a similar transport system across the airway epithelium. This seems unlikely, however, as frusemide is effective only when inhaled, suggesting that it acts on the luminal surface of the epithelium; and such competition does not appear to occur in the kidney, where indomethacin has no effect on renal excretion of frusemide."
Of the various theories that have been advanced to explain the mode of action of frusemide, none is able to explain fully its wide range of action in asthma, the lack ofprotection seen with bumetanide, and the fact that frusemide appears to be effective only when inhaled. Studies suggesting that it acts on neurally mediated bronchoconstriction8 32 do not explain the effects of frusemide on the early and late response to allergen.5 The attraction of our hypothesis that the effects of frusemide in asthma are due to production of an inhibitory prostanoid such as PGE2 is that it offers a plausible explanation for all of these effects. Inhaled frusemide is highly effective in preventing ultrasonically nebulised water bronchoconstriction. Pulm Pharmacol 1989;1:187-91.
